Latest Asian Markets News

Guzman y Gomez (ASX: GYG) reported strong FY26 growth with network sales rising 18% and underlying NPAT up 30%, while completing its exit from the US market and announcing a 48 cents fully franked dividend.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

The Savana US Small Caps Active ETF (ASX: SVNP) returned 2.21% in July 2026, beating the S&P SmallCap 600 benchmark by 5.44%, despite a sharp sell-off in semiconductor and AI infrastructure stocks. The fund’s disciplined, algorithm-driven approach helped navigate volatile market sentiment.

Whitehaven Coal reported a 29% drop in underlying net profit to $227 million for FY26, despite record safety outcomes and successful debt refinancing that lowered funding costs and extended maturities.

BCI Minerals edges closer to first salt shipment at its Mardie Project, with crystallisation underway and 85% construction complete. The company maintains full funding and advances its sulphate of potash opportunity alongside robust sustainability initiatives.

Lark Distilling Co. Ltd grew net sales by 15% in FY26, driven by whisky and international expansion, but posted a $40 million loss after goodwill and inventory impairments.

Regal Asian Investments (ASX:RG8) posted a stellar FY26 with a net profit after tax of $124.8 million, driven by a 52.6% net portfolio return and a 10 cent fully franked final dividend, reflecting strong exposure to Asian semiconductors amid the AI boom.

SGH Ltd (ASX:SGH) reported a 1% rise in underlying EBIT to $1.55 billion for FY26, driven by margin gains at Boral and WesTrac, alongside a disciplined capital allocation strategy including a $500 million on-market buy-back.

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.

Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

Pure Resources has independently confirmed that its Garnet Hills garnet meets international abrasive standards, while pioneering testwork aims to enhance product purity and recovery for defence applications.